Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 1
1987 1
1988 3
1989 3
1990 2
1991 3
1992 6
1993 4
1994 3
1995 8
1996 5
1997 8
1999 6
2000 3
2001 2
2002 2
2003 3
2004 8
2005 6
2006 5
2007 3
2008 5
2009 1
2010 3
2011 5
2012 4
2013 2
2014 2
2015 2
2016 9
2017 2
2018 4
2019 4
2020 2
2021 12
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

140 results
Results by year
Filters applied: . Clear all
Page 1
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Moluçon-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonnière M, El Yamani A, Ghesquières H, Hoang-Xuan K. Soussain C, et al. Among authors: rezai k. Eur J Cancer. 2019 Aug;117:121-130. doi: 10.1016/j.ejca.2019.05.024. Epub 2019 Jul 3. Eur J Cancer. 2019. PMID: 31279304 Clinical Trial.
Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Bautista F, Paoletti X, Rubino J, Brard C, Rezai K, Nebchi S, Andre N, Aerts I, De Carli E, van Eijkelenburg N, Thebaud E, Corradini N, Defachelles AS, Ducassou S, Morscher RJ, Vassal G, Geoerger B. Bautista F, et al. Among authors: rezai k. J Clin Oncol. 2021 Nov 10;39(32):3546-3560. doi: 10.1200/JCO.21.01152. Epub 2021 Aug 4. J Clin Oncol. 2021. PMID: 34347542 Clinical Trial.
Pancreatic transplant imaging.
Yuh WT, Wiese JA, Abu-Yousef MM, Rezai K, Sato Y, Berbaum KS, Kao SC, Hunsicker LG, Corry RJ. Yuh WT, et al. Among authors: rezai k. Radiology. 1988 Jun;167(3):679-83. doi: 10.1148/radiology.167.3.3283838. Radiology. 1988. PMID: 3283838
Tamoxifen therapy in a murine model of myotubular myopathy.
Maani N, Sabha N, Rezai K, Ramani A, Groom L, Eltayeb N, Mavandadnejad F, Pang A, Russo G, Brudno M, Haucke V, Dirksen RT, Dowling JJ. Maani N, et al. Among authors: rezai k. Nat Commun. 2018 Nov 19;9(1):4849. doi: 10.1038/s41467-018-07057-5. Nat Commun. 2018. PMID: 30451841 Free PMC article.
Continuation of high-dose vancomycin despite nephrotoxicity.
Teng CB, Rezai K, Itokazu GS, Xamplas RC, Glowacki RC, Rodvold KA, Weinstein RA, Schwartz DN. Teng CB, et al. Among authors: rezai k. Antimicrob Agents Chemother. 2012 Jun;56(6):3470-1; author reply 3472. doi: 10.1128/AAC.00240-12. Antimicrob Agents Chemother. 2012. PMID: 22581937 Free PMC article. No abstract available.
Are IPL home devices really foolproof?
Schmitt L, Rezai K, Karsai S. Schmitt L, et al. Among authors: rezai k. J Eur Acad Dermatol Venereol. 2016 May;30(5):856-7. doi: 10.1111/jdv.13025. Epub 2015 Feb 24. J Eur Acad Dermatol Venereol. 2016. PMID: 25712139 No abstract available.
Q fever: a biological weapon in your backyard.
Madariaga MG, Rezai K, Trenholme GM, Weinstein RA. Madariaga MG, et al. Among authors: rezai k. Lancet Infect Dis. 2003 Nov;3(11):709-21. doi: 10.1016/s1473-3099(03)00804-1. Lancet Infect Dis. 2003. PMID: 14592601 Review.
140 results